Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:21:13 EDT Sat 13 Jun 2026
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 16 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-06-13 22:16U:ELEKNews ReleaseElektros Inc. Ignites New Momentum Across Lithium, EV Innovation, and Critical Minerals as the Global Electrification Era Accelerates
2026-06-13 21:30U:ELEKNews ReleaseElektros Inc. Powers Ahead as Global Demand for Lithium, EV Innovation, and Critical Minerals Creates New Opportunities for Electrification
2026-06-13 21:15U:ELEKNews ReleaseElektros Inc. Accelerates Its Vision for Lithium, EV Innovation, and the Future of Electrification
2026-06-13 21:00U:ELEKNews ReleasePowering the Future of Electrification
2026-06-13 20:00U:ACDVFNews ReleaseAir Canada and the IAMAW Reach Tentative Agreement on New Contract
2026-06-13 18:15U:CYCLNews ReleaseCycclone, Inc. Announces Agreement in Principle for the Acquisition of AI Robotics Company
2026-06-13 16:00U:ASNDNews ReleasePhase 3 Data Show TransCon(TM) PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
2026-06-13 12:45U:GMABNews ReleaseGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2026-06-13 11:15U:LLYNews ReleaseLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
2026-06-13 11:15U:INCYNews ReleaseIncyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
2026-06-13 09:00U:AGIONews ReleaseAgios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
2026-06-13 08:01U:RYTMNews ReleaseRhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
2026-06-13 07:30U:NTLANews ReleaseIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
2026-06-13 06:33U:JNJNews ReleaseNew TALVEY(TM) (talquetamab-tgvs) plus DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
2026-06-13 06:22U:RDYNews ReleaseDr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif(TM), in the United States
2026-06-13 06:00U:INCYNews ReleaseResults from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi(TM)/Minjuvi(TM)) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival